A Phase IIb, Randomized, Double-blind Study in Subjects With Rheumatoid Arthritis Evaluating the Safety and Efficacy of Evobrutinib Compared With Placebo in Subjects With an Inadequate Response to Methotrexate

Trial Profile

A Phase IIb, Randomized, Double-blind Study in Subjects With Rheumatoid Arthritis Evaluating the Safety and Efficacy of Evobrutinib Compared With Placebo in Subjects With an Inadequate Response to Methotrexate

Recruiting
Phase of Trial: Phase II

Latest Information Update: 03 Jul 2018

At a glance

  • Drugs Evobrutinib (Primary)
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Sponsors EMD Serono Research & Development Institute
  • Most Recent Events

    • 16 May 2018 Planned End Date changed from 21 Apr 2021 to 5 Jul 2020.
    • 16 May 2018 Planned primary completion date changed from 20 Feb 2019 to 10 Jun 2019.
    • 25 Feb 2018 New Source identified and integrated (EudraCT2017-000384-32 European Clinical Trials Database )
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top